Ikigai Pharmatech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.31 M
- Revenue Growth %
- Profit Growth 3047.00%
- Ebitda 74.73%
- Net Worth 43.40%
- Total Assets 514.33%
About Ikigai Pharmatech
Ikigai Pharmatech Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 December 2018 (Six years and one month 9 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.31 M.
Kundu Ruma and Tapas Kundu serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999MH2018PTC318743
-
Company No.
318743
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Dec 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ikigai Pharmatech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kundu Ruma
|
Director | 26-Dec-2018 | Current |
|
Tapas Kundu
|
Director | 26-Dec-2018 | Current |
Financial Performance of Ikigai Pharmatech.
Ikigai Pharmatech Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 3047% increase in profit. The company's net worth Soared by an impressive increase of 43.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ikigai Pharmatech?
Unlock access to Ikigai Pharmatech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹2.31 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.23 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Feb 2024 | Others | ₹2.31 M | Open |
How Many Employees Work at Ikigai Pharmatech?
Unlock and access historical data on people associated with Ikigai Pharmatech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ikigai Pharmatech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ikigai Pharmatech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.